Citation Impact
Citing Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
2005 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Diet and Lifestyle Recommendations Revision 2006
2006 Standout
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas
2007 Standout
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Supplemental and Complementary Alternatives to Hormone Replacement Therapy
1999
Homocysteine and vascular disease
1999 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
2007 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Hyperhomocysteinaemia
1999
Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular Cancer
1987
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
2008 Standout
Testicular Germ-Cell Cancer
1997 Standout
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
A view on drug resistance in cancer
2019 StandoutNature
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
2008 StandoutNature
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
2006 Standout
Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the Kumihama study
2003
Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979–1989)
1991
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
1995
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
2002 Standout
Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us?
2002
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
2008 Standout
Paclitaxel (Taxol)
1995 Standout
Delirium as a Predictor of Mortality in Mechanically Ventilated Patients in the Intensive Care Unit
2004 Standout
Polymorphisms in the CBS Gene Associated with Decreased Risk of Coronary Artery Disease and Increased Responsiveness to Total Homocysteine Lowering by Folic Acid
2000
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death
2004 Standout
Folic Acid and Homocyst(e)ine Metabolic Defects and the Risk of Placental Abruption, Pre-eclampsia and Spontaneous Pregnancy Loss: A Systematic Review
1999
Neural-Tube Defects
1999 Standout
Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma
2002
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.
1994
After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer.
1994
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
2006 Standout
MTHFR 677C→T Polymorphism and Risk of Coronary Heart Disease
2002
A Second Common Mutation in the Methylenetetrahydrofolate Reductase Gene: An Additional Risk Factor for Neural-Tube Defects?
1998
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Upstream and downstream of mTOR
2004 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Fluorescent and colorimetric probes for detection of thiols
2010 Standout
Chemotherapy and the war on cancer
2005 Standout
Homocysteine and Risk of Ischemic Heart Disease and Stroke
2002 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Homocysteine and Risk of Cardiovascular Disease Among Postmenopausal Women
1999
The Effect of Folic Acid Fortification on Plasma Folate and Total Homocysteine Concentrations
1999 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Vitamin Intervention for Stroke Prevention (VISP) Trial: Rationale and Design
2001
Homocysteine and cardiovascular disease:
2002
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 Standout
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors
1990
Atherosclerosis
2000 StandoutNature
Folic acid improves arterial endothelial function in adults with hyperhomocystinemia
1999
Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma
1992
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
2000 Standout
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.
1990
Homocysteine and atherosclerosis
1999
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study
2001
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
2004
Homocyst(e)ine, Diet, and Cardiovascular Diseases
1999
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
1994
Transformational, transactional, and laissez-faire leadership styles: A meta-analysis comparing women and men.
2003 Standout
Cancer of the Ovary
2004 Standout
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes
2004 StandoutNobel
Randomized Trial of Folic Acid Supplementation and Serum Homocysteine Levels
2001
Relation of Plasma Homocyst(e)ine to Cerebral Infarction and Cerebral Atherosclerosis
1998
Vitamin Supplementation Reduces Blood Homocysteine Levels
1998
Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.
1992
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
Hyperhomocysteinemia, Atherosclerosis and Thrombosis
1999
Endothelial Nitric Oxide Synthase in Vascular Disease
2006 Standout
Common Methylenetetrahydrofolate Reductase Gene Mutation Leads to Hyperhomocysteinemia but Not to Vascular Disease
1998
Hyperhomocysteinemia and Other Inherited Prothrombotic Conditions in Young Adults With a History of Ischemic Stroke
2002
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
1993
Cobalamin and Folate Evaluation: Measurement of Methylmalonic Acid and Homocysteine vs Vitamin B12 and Folate
2000
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
2006 Standout
Monitoring Delirium in Critically Ill Patients
2003
Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
1990
Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections.
1993
Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence
1999
Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials
2005
Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780
2001
The Management of Patients with Nonseminomatous Germ Cell Tumors of the Testis with Serologic Disease Only After Orchiectomy
1994
Endothelial dysfunction in patients with recent myocardial infarction and hyperhomocysteinaemia: effects of vitamin supplementation
2004
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
Evaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks?
1999
Dysregulation of the TSC-mTOR pathway in human disease
2004 Standout
Works of R. Gluckman being referenced
Reduction of Plasma Homocyst(e)ine Levels by Breakfast Cereal Fortified with Folic Acid in Patients with Coronary Heart Disease
1998
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.
1986
The Effects of Folic Acid Supplementation on Plasma Total Homocysteine Are Modulated by Multivitamin Use and Methylenetetrahydrofolate Reductase Genotypes
1997
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
1999